Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) has become a standard treatment of locally advanced rectal adenocarcinomas. The clinical stages II (cT3-4, N0, M0) and III (cT1-4, N+, M0) according to International Union Against Cancer (IUCC) are concerned. It can reduce tumor volume and subsequently lead to an increase in complete resections (R0 resections), shows less toxicity, and improves local control rate. The aim of this review is to summarize actual approaches, main problems, and discrepancies in the treatment of locally advanced rectal adenocarcinomas.
Neoadjuvant treatment in rectal cancer: actual status / I. Garajovà; S. Di Girolamo; F. de Rosa; J. Corbelli; V. Agostini; G. Biasco; G. Brandi. - In: CHEMOTHERAPY RESEARCH AND PRACTICE. - ISSN 2090-2107. - STAMPA. - 2011:(2011), pp. 1-12. [10.1155/2011/839742]
Neoadjuvant treatment in rectal cancer: actual status.
GARAJOVA, INGRID;BIASCO, GUIDO;BRANDI, GIOVANNI
2011
Abstract
Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) has become a standard treatment of locally advanced rectal adenocarcinomas. The clinical stages II (cT3-4, N0, M0) and III (cT1-4, N+, M0) according to International Union Against Cancer (IUCC) are concerned. It can reduce tumor volume and subsequently lead to an increase in complete resections (R0 resections), shows less toxicity, and improves local control rate. The aim of this review is to summarize actual approaches, main problems, and discrepancies in the treatment of locally advanced rectal adenocarcinomas.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
